In an effort to help our PWS community better understand its SCOUT-015 trial, Radius Health has released several resources about the process of the study, trial sites, and about their drug RAD011 a synthetic cannabidiol oral solution, which is being studied as a possible treatment for hyperphagia and related behaviors in Prader-Willi syndrome.
Click on the buttons below to download these helpful documents. You can also find a comprehensive list of these RAD011 trial sites and their enrollment guidelines at www.clinicaltrials.gov. If you have any questions, contact email@example.com.
About RAD011 and the SCOUT-015 Clinical Trial
Radius Health's RAD011 is a synthetic cannabidiol oral solution, which is being studied as a possible treatment for hyperphagia and related behaviors in Prader-Willi syndrome.
According to Radius Health, the SCOUT-015 clinical study is a "global randomized, double-blind, placebo-controlled study in PWS with around 200 patients, and a seamless phase 2/3 design to allow for evaluation of multiple dose groups and Intent-To-Treat efficacy analysis with both Phase 2 and Phase 3 cohorts." The study is looking to enroll individuals living with PWS who are between the ages of 12-65.
Currently, there are nine available clinical trial sites with more planned.